Literature DB >> 35713676

[Liver metastases of neuroendocrine tumors].

S Nadalin1, M Peters2, A Königsrainer2.   

Abstract

Neuroendocrine liver metastases (NELM) are very heterogeneous with respect to the clinical presentation and the prognosis. The treatment of NELMs requires a multidisciplinary approach and patients with NELM should be referred to a specialized center. When possible, the resection of NELMs provides the best long-term results. The general selection criteria for liver resection include an acceptable general physical condition for a large liver operation, tumors with a favorable differentiation grade 1 or 2, a lack of extrahepatic lesions, a sufficient residual liver volume and the possibility to resect at least 70% of the metastases. Supplementary treatment, including simultaneous liver ablation, are generally safe and can increase the number of patients who can be considered for surgery. For patients with resectable NELM, the resection of the primary tumor is recommended either in a 2-stage or combined procedure. In selected patients with nonresectable NELM a liver transplantation can be carried out, which can be associated with excellent long-term results.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Classification; Indications; Interventional treatment; Liver transplantation; Selection criteria; Surgical treatment

Mesh:

Year:  2022        PMID: 35713676     DOI: 10.1007/s00104-022-01656-1

Source DB:  PubMed          Journal:  Chirurgie (Heidelb)        ISSN: 2731-6971


  65 in total

Review 1.  Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.

Authors:  Eliano Bonaccorsi-Riani; Carlos Apestegui; Anne Jouret-Mourin; Christine Sempoux; Pierre Goffette; Olga Ciccarelli; Ivan Borbath; Catherine Hubert; Jean François Gigot; Ziad Hassoun; Jan Lerut
Journal:  Transpl Int       Date:  2010-05-05       Impact factor: 3.782

Review 2.  [Preconditioning of the liver].

Authors:  I Capobianco; J Strohäker; A Della Penna; S Nadalin; A Königsrainer
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

3.  Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study.

Authors:  Fabian Bartsch; Verena Tripke; Janine Baumgart; Maria Hoppe-Lotichius; Stefan Heinrich; Hauke Lang
Journal:  Int J Surg       Date:  2019-05-20       Impact factor: 6.071

4.  Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases.

Authors:  P Bhosale; A Shah; W Wei; G Varadhachary; V Johnson; V Shah; V Kundra
Journal:  Eur Radiol       Date:  2012-08-30       Impact factor: 5.315

Review 5.  Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?

Authors:  M Biolato; G Marrone; S Racco; C Di Stasi; L Miele; G Gasbarrini; R Landolfi; A Grieco
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-04       Impact factor: 3.507

6.  The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.

Authors:  J Philip Boudreaux; David S Klimstra; Manal M Hassan; Eugene A Woltering; Robert T Jensen; Stanley J Goldsmith; Charles Nutting; David L Bushnell; Martyn E Caplin; James C Yao
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 7.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

8.  The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Authors:  Anthony J Chambers; Janice L Pasieka; Elijah Dixon; Otto Rorstad
Journal:  Surgery       Date:  2008-10       Impact factor: 3.982

9.  A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases.

Authors:  Camilo Correa-Gallego; Yuman Fong; Mithat Gonen; Michael I D'Angelica; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham
Journal:  Ann Surg Oncol       Date:  2014-06-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.